KCEA-APO(a)-LRx Trial: Anti-sense Oligonucleotide Shows Promise in Reducing Blood Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease
A study led by Dr. Sotirios Tsimikas published in the New England Journal of Medicine showed that the hepatocyte-directed antisense oligonucleotide APO(a)-LRx significantly... Read more.